Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Kidney and Urinary TractDRG 683-renal-failure-with-cc
    Ask Trek AI about this page

    Renal Failure with CC: Inpatient Reimbursement Overview

    DRG 683 addresses inpatient renal failure cases with at least one Complication or Comorbidity and defines the clinical scope for payment impact. It matters because the Complication or Comorbidity level influences Medicare Severity Diagnosis-Related Group assignment and resultant inpatient reimbursement.

    Customize your policy alerts

    Sign up for drg 683 policy alerts

    Get alerted when payer policies referencing 683 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 683 Overview

    DRG 683 covers inpatient stays for renal failure with at least one Complication or Comorbidity. It encompasses acute and chronic kidney failure presentations when an associated condition increases resource use. This Diagnosis-Related Group matters for Medicare payment because the presence of a Complication or Comorbidity elevates relative payment compared with renal failure cases without comorbidities, reflecting higher expected hospital resource consumption. Accurate clinical coding of renal failure and related comorbid conditions affects reimbursement and case mix classification.

    Table of contents

    Progress1 / 5

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    National Payment Rates

    Commercial payer rates for DRG 683 span roughly from $8.5K to $18K across the payers listed, with individual payer medians ranging from $8.5K (BCBS) up to $16K (Aetna). The widest spread between payer medians and maximums appears among Anthem and Aetna payers, with maximums reported up to $34K and $25K respectively. See the table and chart below for payer-specific distributions and percentile detail.

    The CMS 2023 data represent national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 683. These values reflect nationwide Medicare payment and charge averages for the covered cases in 2023.

    Average Total PaymentAverage Submitted ChargesAverage Medicare PaymentTotal Discharges
    $8.3K$39K$6.4K82K

    Patient Population

    The patient population for DRG 683 skews toward older adults and is primarily Medicare-age rather than predominantly working-age. Commercial payers cover a portion of cases, indicating a mixed but Medicare-leaning population. Expect a larger share of discharges to be from Medicare beneficiaries compared with commercial insurers.

    State Payment Rates

    State: Alaska1 / 49

    Alaska Benchmarks

    DRG 683 in Alaska shows a narrow rate band for Anthem and Blue Cross Blue Shield at $14K each, while Cigna displays a broader distribution with a mean of $21K and a max of $35K, producing the largest intra-state variance. The presence of Cigna’s higher mean stands out versus national medians and contributes the most notable deviation from national averages. Refer to the table and chart below for payer-specific percentiles and the full distribution.

    Key Insights for Alaska

    • Anthem is the highest-paying payer in Alaska (mean $14K), while Blue Cross Blue Shield is the lowest-paying payer (mean $14K); Cigna shows the widest spread with a mean of $21K and a max of $35K.
    • Alaska rates are generally clustered at $14K for Anthem and BCBS, but Cigna’s mean of $21K meaningfully exceeds the clustered state rates and is higher than typical national medians, representing the most notable deviation from national patterns.

    Clinical Trials

    • Acute renal support and early intervention trials: Studies examining timing, modality, and protocols for acute kidney replacement therapies (including intensive hemodialysis/CRRT initiation thresholds, anticoagulation strategies, and fluid management) in hospitalized patients with acute renal failure complicated by comorbidities. These trials enroll patients with new or worsening renal failure during an inpatient stay—often critically ill or hemodynamically unstable—and test whether earlier or protocolized interventions reduce progression to sustained renal replacement therapy or multiorgan failure. This research is directly relevant to inpatient clinicians and payers because optimal acute management may shorten length of stay, lower ICU resource use, and reduce downstream costs associated with chronic dialysis dependence.
    • Comparative effectiveness studies of bundled inpatient care pathways and complication prevention: Trials or pragmatic comparative studies that evaluate care bundles (e.g., nephrotoxin stewardship, contrast-sparing imaging protocols, optimized hemodynamic management, and standardized electrolyte/acid–base protocols) versus usual care for patients admitted with renal failure and at-risk comorbid conditions. These studies target heterogeneous hospital populations with renal dysfunction and common CCs (sepsis, heart failure, liver disease) to determine which multidisciplinary pathways reduce in-hospital complications, readmissions for renal or cardiovascular issues, and rates of progression to chronic kidney disease. Findings inform hospitals and payers about which care coordination and quality improvement investments most effectively reduce complications and total cost of care for this high-risk DRG.
    • Post-discharge outcomes and transitional care interventions: Research focused on post-discharge follow-up models, such as early nephrology clinic visits, pharmacist-led medication reconciliation, home lab monitoring, or telehealth monitoring for patients discharged after an inpatient renal failure episode to prevent readmission and monitor recovery of renal function. These cohort studies or randomized trials enroll survivors of inpatient renal failure—often older adults with multimorbidity and polypharmacy—and measure outcomes like renal recovery, 30- and 90-day readmissions, and progression to chronic dialysis. Payers and healthcare systems use this evidence to design transitional care programs that reduce costly readmissions and long-term dialysis initiation, aligning clinical outcomes with reimbursement and value-based care goals.

    Related Codes

    650-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITH-MCC

    Kidney Transplant with Hemodialysis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    651-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITHOUT-MCC

    Kidney Transplant with Hemodialysis without MCC: Inpatient Reimbursement Overview

    652-KIDNEY-TRANSPLANT

    Kidney Transplant: Inpatient Reimbursement Overview

    653-MAJOR-BLADDER-PROCEDURES-WITH-MCC

    Major Bladder Procedures with MCC: Inpatient Reimbursement Overview

    654-MAJOR-BLADDER-PROCEDURES-WITH-CC

    Major Bladder Procedures with CC: Inpatient Reimbursement Overview

    655-MAJOR-BLADDER-PROCEDURES-WITHOUT-CC-MCC

    Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

    656-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Neoplasm with MCC: Inpatient Reimbursement Overview

    657-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-CC

    Kidney and Ureter Procedures for Neoplasm with CC: Inpatient Reimbursement Overview

    658-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITHOUT-CC-MCC

    Kidney and Ureter Procedures for Neoplasm without CC/MCC: Inpatient Reimbursement Overview

    659-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Non-Neoplasm with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 41

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    Mean Rates by Payer — National — DRG 683
    Mean Rates by Payer — Alaska — DRG 683